The news: Content from Healthline.com, one of the most-visited medical information websites, will power a new product called Healthline AI, which lets consumers ask health-related questions and search medically reviewed articles. Healthline AI will also leverage content from Healthline’s affiliated health brands, including Healthgrades, Medical News Today, and Psych Central.

Healthline AI is launching with an initial focus on type 2 diabetes, though it plans to add content about other conditions over time. For example, a user with type 2 diabetes could ask about GLP-1 medications, prompting the chatbot to surface answers drawn from Healthline’s resources. The tool can then route users to Healthgrades to find and book an appointment with a physician.

Why it matters: Healthline AI is a defensive response to AI-driven traffic loss to health information websites.

Medical information websites are especially vulnerable to traffic losses from AI Overviews. While many publishers are seeing fewer visits as search engines answer queries directly on results pages, health websites have been hit particularly hard. Health-related searches trigger AI-generated summaries more often than most other query categories, per BrightEdge, reducing the need for users to click through to the underlying websites. Publishers like Healthline are often cited in AI Overviews, but those citations don’t guarantee clicks to the site.

And as consumers turn to AI chatbots for health guidance, it lessens the dependence on visiting medical information websites directly. Researching conditions and symptoms and exploring treatment options are the top two reasons US adults use AI tools for health information, per EMARKETER’s January 2026 US Digital Health survey. Both rank among the primary reasons consumers visit Healthline.

Implications for healthcare and pharma marketers: Sites like Healthline primarily attract users seeking health information related to specific conditions or treatments, not consumers casually browsing broad wellness content. That user intent makes health information sites a natural fit for pharma brands that want to align messages about their treatments with relevant disease categories. However, as health information sites lose traffic, marketers that once advertised in these endemic environments need to rethink their strategies. For context, 19% of consumers said they saw healthcare or pharma ads on health-focused sites like Healthline and WebMD in the past year, per EMARKETER’s January 2026 US Digital Health survey.

By rolling out AI agents, online health publishers are adapting to changing consumer expectations around how health information is accessed, while also creating a familiar setting for healthcare and pharma advertising. However, marketing investment will hinge on publishers’ ability to prove that these AI-powered answer products deliver enough value to keep patients engaged rather than defaulting to general-purpose LLMs.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.